Cargando…
Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy
INTRODUCTION: Although end-stage renal disease (ESRD) and surrogate markers for renal dysfunction are frequently used as outcome markers for IgA nephropathy, the clinical course after reaching ESRD is not well documented. This study examined outcomes of progression to ESRD and age at death in a coho...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762959/ https://www.ncbi.nlm.nih.gov/pubmed/29340319 http://dx.doi.org/10.1016/j.ekir.2017.08.008 |
_version_ | 1783291799805100032 |
---|---|
author | Hastings, M. Colleen Bursac, Zoran Julian, Bruce A. Villa Baca, Emanuel Featherston, Jennifer Woodford, Susan Y. Bailey, Lisa Wyatt, Robert J. |
author_facet | Hastings, M. Colleen Bursac, Zoran Julian, Bruce A. Villa Baca, Emanuel Featherston, Jennifer Woodford, Susan Y. Bailey, Lisa Wyatt, Robert J. |
author_sort | Hastings, M. Colleen |
collection | PubMed |
description | INTRODUCTION: Although end-stage renal disease (ESRD) and surrogate markers for renal dysfunction are frequently used as outcome markers for IgA nephropathy, the clinical course after reaching ESRD is not well documented. This study examined outcomes of progression to ESRD and age at death in a cohort of adults with IgA nephropathy with a long duration of follow-up. METHODS: Patient and kidney survival of 251 adult patients with IgA nephropathy from the southeastern United States diagnosed between January 1, 1976 and December 31, 2005 were analyzed. RESULTS: Median age at diagnosis was 36.9 years. Most patients were men (69%) and Caucasian (95%). Only 46% had an estimated glomerular filtration rate >60 ml/min per 1.73 m(2) at diagnosis. Mean follow-up time from time of diagnostic biopsy to death or end of study was 19.3 years. Of 251 patients, 132 (53%) progressed to ESRD and 97 (39%) died. Life expectancy was reduced by 10.1 years, with a median observed age of death at 65.7 years and a median expected age at death of 75.8 years. Eighty-three percent of the deaths occurred after progression to ESRD. CONCLUSION: Life expectancy is substantially reduced for patients diagnosed with IgA nephropathy in the southeastern United States. |
format | Online Article Text |
id | pubmed-5762959 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-57629592018-01-16 Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy Hastings, M. Colleen Bursac, Zoran Julian, Bruce A. Villa Baca, Emanuel Featherston, Jennifer Woodford, Susan Y. Bailey, Lisa Wyatt, Robert J. Kidney Int Rep Clinical Research INTRODUCTION: Although end-stage renal disease (ESRD) and surrogate markers for renal dysfunction are frequently used as outcome markers for IgA nephropathy, the clinical course after reaching ESRD is not well documented. This study examined outcomes of progression to ESRD and age at death in a cohort of adults with IgA nephropathy with a long duration of follow-up. METHODS: Patient and kidney survival of 251 adult patients with IgA nephropathy from the southeastern United States diagnosed between January 1, 1976 and December 31, 2005 were analyzed. RESULTS: Median age at diagnosis was 36.9 years. Most patients were men (69%) and Caucasian (95%). Only 46% had an estimated glomerular filtration rate >60 ml/min per 1.73 m(2) at diagnosis. Mean follow-up time from time of diagnostic biopsy to death or end of study was 19.3 years. Of 251 patients, 132 (53%) progressed to ESRD and 97 (39%) died. Life expectancy was reduced by 10.1 years, with a median observed age of death at 65.7 years and a median expected age at death of 75.8 years. Eighty-three percent of the deaths occurred after progression to ESRD. CONCLUSION: Life expectancy is substantially reduced for patients diagnosed with IgA nephropathy in the southeastern United States. Elsevier 2017-08-24 /pmc/articles/PMC5762959/ /pubmed/29340319 http://dx.doi.org/10.1016/j.ekir.2017.08.008 Text en © 2017 International Society of Nephrology. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Clinical Research Hastings, M. Colleen Bursac, Zoran Julian, Bruce A. Villa Baca, Emanuel Featherston, Jennifer Woodford, Susan Y. Bailey, Lisa Wyatt, Robert J. Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy |
title | Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy |
title_full | Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy |
title_fullStr | Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy |
title_full_unstemmed | Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy |
title_short | Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy |
title_sort | life expectancy for patients from the southeastern united states with iga nephropathy |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762959/ https://www.ncbi.nlm.nih.gov/pubmed/29340319 http://dx.doi.org/10.1016/j.ekir.2017.08.008 |
work_keys_str_mv | AT hastingsmcolleen lifeexpectancyforpatientsfromthesoutheasternunitedstateswithiganephropathy AT bursaczoran lifeexpectancyforpatientsfromthesoutheasternunitedstateswithiganephropathy AT julianbrucea lifeexpectancyforpatientsfromthesoutheasternunitedstateswithiganephropathy AT villabacaemanuel lifeexpectancyforpatientsfromthesoutheasternunitedstateswithiganephropathy AT featherstonjennifer lifeexpectancyforpatientsfromthesoutheasternunitedstateswithiganephropathy AT woodfordsusany lifeexpectancyforpatientsfromthesoutheasternunitedstateswithiganephropathy AT baileylisa lifeexpectancyforpatientsfromthesoutheasternunitedstateswithiganephropathy AT wyattrobertj lifeexpectancyforpatientsfromthesoutheasternunitedstateswithiganephropathy |